ERBB2 and breast cancer: Second, although lapatinib also possesses inhibitory activity against EGFR, our data showed that treatments with specific EGFR inhibitors, including erlotinib and gefitinib, suppress rather than induce p65 phosphorylations in both HER2-positive BT474 and triple-negative MDA-MB-231 breast cancer cells (Figure 1E and F).